StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) income statement

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)

Close on Nov 18, 2026Market cap $2.15MP/E –Yield –

BioNexus Gene Lab Corp income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
12.3%
Operating margin
-81.8%
Net margin
-82.4%
Return on equity, FY2025
-35.2%

Financial strength

Current ratio
6.08
Debt to equity
–
Debt to assets
–
Cash to current liabilities
151.6%

Valuation

P/E ratio
–
Price to sales
0.69
Price to book
0.28
Dividend yield
–

See a number that looks wrong?